Investor Presentaiton slide image

Investor Presentaiton

SARS-COV-2 clinical trial started in Argentina Investigator initiated trial at: Centro de educación médica e investigaciones clinicas (CEMIC) Instituto Milstein-CONICET Buenos Aires, Capital Federal, Argentina Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease (CARR-COV-02) Study Design Study Type Estimate Enrollment Allocation Intervention Model Intervention Model Description Masking Primary Purpose Official Title Actual Study Start Date Estimated Primary Completion Date Estimated Study Completion Date Interventional (Clinical Trial) 400 participants Randomized Parallel Assignment Multicenter, randomized, double blind compared vs. placebo Double (Participant, Investigator) Prevention Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 (CARR-COV-02) July 24, 2020 October 30, 2020 November 30, 2020 marino med Source: https://www.clinicaltrials.gov/ct2/show/NCT04521322. 80
View entire presentation